MRK vs DGX
By Alex · Tickerpine
Merck & Co., Inc. vs Quest Diagnostics Incorporated, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | DGX |
|---|---|---|
| Price | $147.76 | $259.60 |
| Market cap | $364.26B | $28.56B |
| P/E ratio | 149.3 | 25.9 |
| ROE | 5.06% | 15.32% |
| Profit margin | 3.64% | 9.54% |
| Revenue growth | 4.70% | 10.00% |
| Dividend yield | 2.30% | 1.33% |
| Beta | 0.12 | 0.55 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs DGX in plain English
- MRK is the bigger company — about 12.8× the market cap of DGX.
- DGX is cheaper on earnings (P/E 25.9 vs 149.3).
- DGX earns a higher return on equity (15% vs 5%).
- DGX is growing revenue faster (10% vs 5%).
- MRK has the higher dividend yield (2.30% vs 1.33%).
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
DGX return calculator
See what $1,000 in Quest Diagnostics Incorporated would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.